Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 6Brain Neoplasms 3Pain 2Neuralgia 2Glioma 2Depression 2Visceral Pain 1Rectal Neoplasms 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Neurologic Manifestations 1Language Disorders 1Headache 1Glioblastoma 1Fatigue 1Cognitive Dysfunction 1Carcinoma, Renal Cell 1Cancer Survivor 1Anxiety Disorders 1Agnosia 1Acromegaly 1

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 20Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × Transcranial Magnetic Stimulation × Clear all
NCT02283944 2021-09-20

TMS Electrochemotherapy for Glioblastoma Multiforme

University of Aarhus

Phase 2 Withdrawn
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡